Design, synthesis, and antidiabetic evaluation of triazolopyrimidine thioacetamides as potent and selective α-glucosidase inhibitors
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.109482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Fariba Peytam und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Drug Design and Development Research Cen…. Hauptthemen laut MEDLINE: Glycoside Hydrolase Inhibitors, Hypoglycemic Agents, alpha-Glucosidases, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Tehran University of Medical Sciences.
Abstract (Originalsprache)
Diabetes mellitus is a global health challenge characterized by chronic hyperglycemia. α-Glucosidase inhibitors, like acarbose, are pivotal in managing postprandial blood glucose levels but are often associated with gastrointestinal side effects. This study aimed to rationally design and synthesize a library of 2-((6-amino-5,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)thio)-N-arylacetamide derivatives (15a-15ae) as potent and selective α-glucosidase inhibitors. All 31 target compounds exhibited inhibitory activity (IC50 ranging from 7.09 μM to 245.57 μM) under assay conditions where the reference drug, acarbose, exhibited an IC50 value of 750.67 μM. The most potent compound, 15o (IC50 = 7.09 ± 0.2 μM), demonstrated approximately 106-fold higher potency than acarbose under the identical assay conditions. Kinetic analysis indicated that 15o acted as a competitive inhibitor (Kᵢ = 6.9 μM). Moreover, this compound did not show α-amylase inhibitory activity and cytotoxicity at concentration of 100 μM, showing preliminary indications of favorable safety and selectivity. Spectroscopic studies (CD, fluorescence) and computational analyses (model performance and augmentation, docking, and MD simulations) confirmed the strong binding affinity and stabilization of compound 15o within the enzyme's active site. In vivo evaluation in a diabetic rat model demonstrated that 15o (30 mg/kg BW) significantly reduced fasting blood glucose, improved glucose tolerance in OGTT, reduced HbA1c levels to near-normal ranges, and restored hepatic and pancreatic histology, with effects better than those observed with acarbose in this model. Compound 15o also exhibited acceptable acute toxicity profiles. These findings introduced compound 15o as a promising lead candidate for further structural development of anti-diabetic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran Universit…
- Faculty of Pharmacy, Final International University, Catalkoy, Kyrenia via Mersin, 10, TRNC, Turkey.
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
- Eastern Mediterranean University, Faculty of Pharmacy, Famagusta, TRNC, via Mersin, 10, Turkey.
- Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Förderung
- Tehran University of Medical Sciences
Zitieren
APA
Peytam, F., Norouzbahari, M., Bayati, B., Gülcan, H. O., Sheibani, V., Barazandeh Tehrani, M., Mojtabavi, S., Faramarzi, M. A., Ghasemi, F., Torabi, M., Payab, M., Safari, F., Firoozpour, L., & Foroumadi, A. (2026). Design, synthesis, and antidiabetic evaluation of triazolopyrimidine thioacetamides as potent and selective α-glucosidase inhibitors. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109482
Vancouver
Peytam F, Norouzbahari M, Bayati B, Gülcan HO, Sheibani V, Barazandeh Tehrani M, et al. Design, synthesis, and antidiabetic evaluation of triazolopyrimidine thioacetamides as potent and selective α-glucosidase inhibitors. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109482
BibTeX
@article{Peytam2026,
author = {Peytam, Fariba and Norouzbahari, Maryam and Bayati, Bahareh and Gülcan, Hayrettin Ozan and Sheibani, Vahid and Barazandeh Tehrani, Maliheh and Mojtabavi, Somayeh and Faramarzi, Mohammad Ali and Ghasemi, Fahimeh and Torabi, Mohammadreza and Payab, Meghdad and Safari, Fatemeh and Firoozpour, Loghman and Foroumadi, Alireza},
title = {Design, synthesis, and antidiabetic evaluation of triazolopyrimidine thioacetamides as potent and selective α-glucosidase inhibitors},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.109482}
}
EUVIMED